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Maternal hypothyroxinemia in early pregnancy is often asso-
ciated with irreversible effects on neuropsychomotor devel-
opment. To evaluate fetal tissue exposure to maternal thyroid
hormones up to midgestation, we measured total T4 and free
T4 (FT4), T3, rT3, TSH, and possible binding proteins in first
trimester coelomic and amniotic fluids and in amniotic fluid
and fetal serum up to 17 wk. Samples were obtained before
interruption of maternal-fetal connections. The concentra-
tions in fetal compartments of T4 and T3 are more than 100-fold
lower than those in maternal serum, and their biological rel-
evance for fetal development might be questioned. We found,
however, that in all fetal fluids the concentrations of T4 avail-
able to developing tissues, namely FT4, reach values that are
at least one third of those biologically active in their euthyroid
mothers. FT4 levels in fetal fluids are determined by both their
T4-binding protein composition and the T4 or FT4 in maternal
serum. The binding capacity is determined ontogenically, is
independent of maternal thyroid status, and is far in excess of
the T4 in fetal fluids. Thus, the availability of FT4 for embry-
onic and fetal tissues would decrease in hypothyroxinemic
women, even if they were euthyroid. A decrease in the avail-
ability of FT4, a major precursor of intracellular nuclear
receptor-bound T3, may result in adverse effects on the timely
sequence of developmental events in the human fetus. These
findings ought to influence our present approach to maternal
hypothyroxinemia in early pregnancy regardless of whether
TSH is increased or whether overt or subclinical hypothy-
roidism is detected. (J Clin Endocrinol Metab 87: 1768–1777,
2002)
THYROID HORMONES are essential for fetal brain de-velopment, but the timing of onset of the different
events that are thyroid hormone dependent has not yet been
clearly defined, in particular for the first trimester of human
development (1). This uncertainty persists despite the dem-
onstration that nuclear TR, partially occupied by T3, are
present in first trimester human fetal brain tissue (2–4). This
suggests that thyroid hormone-mediated effects may already
occur in the early fetus.
It is important to clarify this point. There is increasing
evidence from epidemiological and experimental data (5)
that first trimester maternal thyroid status is pivotal for the
outcome of pregnancy (6) and for the neuropsychomotor
development of the child (7, 8). Efforts to detect and prevent
maternal hypothyroxinemia in early pregnancy appear fully
justified (5). Indeed, neurodevelopment defects, including an
increased probability of cerebral palsy, may be 150 times
more frequent than those resulting from untreated congen-
ital hypothyroidism.
More direct evidence obtained from human fetal fluids is
still needed to better understand the maternal-fetal thyroid
hormone relationships before the onset of fetal thyroid se-
cretion. Available information up to midgestation is scarce,
especially for fetal fluid samples obtained before interrup-
tion of maternal to fetal connections. During this period two
distinct modes of maternal-fetal nutrient transfer occur se-
quentially. For most of the first trimester the human fetus is
surrounded by two distinct fluid cavities separated from
each other by a thin membrane (Fig. 1A): the inner, or am-
niotic, cavity contains the fetus, and the outer, or exocoelo-
mic, cavity separates the amniotic cavity from the placenta
and contains the secondary yolk sac (9). The secondary yolk
sac is directly connected to the fetal digestive tract and cir-
culation. The investigation of early fetal fluids has demon-
strated that the exocoelomic cavity is the site of important
molecular exchanges between the mother and the fetus (10–
13). The coelomic fluid results from an ultrafiltrate of ma-
ternal serum with the addition of specific placental and sec-
ondary yolk sac bioproducts (10–12, 14). The exocoelomic
cavity is clearly a physiological liquid extension of the early
placenta that may act as a reservoir for nutrients needed by
the developing fetus (13). We previously demonstrated that
T4 (and possibly T3) is indeed present in coelomic fluid (CF)
samples as early as 5.6 wk gestation (15). These preliminary
data show that maternal thyroid hormones are potentially
available to early fetal tissues, but raise new questions about
whether the thyroid hormone concentrations found inside
Abbreviations: AF, Amniotic fluid; CF, coelomic fluid; 5D-I, type I
5-iodothyronine deiodinase; 5D-II, type II 5-iodothyronine deiodi-
nase; 5D-III, inner ring iodothyronine deiodinase; FS, fetal serum; FT3,
free T3; FT4, free T4; MS, maternal serum; rT2, 3,3-diiodo-l-thyronine;
TBG, T4-binding globulin; TTR, transthyretin.
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the gestational sac could be biologically relevant for the oc-
cupation of nuclear TR in the fetal brain.
The second mode of transfer starts at the end of the first
trimester. The secondary yolk sac and two thirds of the
placental mass degenerate, and the exocoelomic cavity is
progressively obliterated by the growing amniotic cavity
containing the fetus (Fig. 1B). These major anatomical trans-
formations modify considerably the spatial relationships be-
tween maternal tissue and developing fetus, and, conse-
quently, the maternal-fetal exchange pathways. From 11–12
wk onward, maternal nutrients, including thyroid hormone,
are transferred via the placenta directly into the fetal circu-
lation. Thyroid hormone levels in fetal serum (FS) had only
occasionally been measured during the same period (16). The
aim of this study was to further investigate the distribution
of thyroid hormones inside the first trimester exocoelomic
and amniotic cavities, to determine thyroid hormone concen-
trations in the second trimester amniotic cavity and fetal cir-
culation, and to quantify the concentrations of the T4 likely to
be available to fetal tissues, namely those of free T4 (FT4), and
interrelationships with maternal circulating iodothyronines.
Materials and Methods
Subjects and samples
We have studied four series of samples. Series A and B consisted of
matched samples of CF, amniotic fluid (AF), and maternal serum (MS)
at 5.6–12 wk gestation. Series A corresponds to the 13 women presented
in our previous report (15), all of whom were Caucasian. Series B com-
prised samples from 20 women collected in a different area of London;
12 were from ethnic minorities (7 black African and 5 Asian). The third
series of samples (C) included matched samples of CF, AF, and MS at
7.6–11.6 wk (n  15) and of AF, FS, and MS at 11.6–17.1 wk gestation
(n  28); 9 women were black African, and 4 were Asian. Series D
consisted of first trimester CF and AF samples (n  32) for which MS
was not available. These samples were used for necessary verifications
of some of the analytical procedures (HPLC; percent FT4 and percent
FT3). All samples were collected before elective surgical termination of
pregnancy under general anesthesia. Gestational age was determined
from the first day of the last menstrual period and was confirmed by
ultrasound measurement of the fetal crown-rump length. Written con-
sent was obtained from each woman after receiving complete informa-
tion on the procedure. The study included only uncomplicated preg-
nancies and was approved by University College London Hospitals
committee on the ethics of human research.
CF and AF samples were obtained by trans-vaginal puncture under
sonographic guidance (10, 12, 13). The first 0.2 ml of each fluid was
discarded to decrease the risk of contamination by maternal blood. Fetal
blood samples of 2.0–5.0 ml were aspirated by ultrasonographically
guided intracardiac puncture (13). The samples were collected in hep-
arinized tubes, centrifuged within 60 min of collection. In all cases,
maternal venous blood was obtained during the surgical procedure. FS
and MS samples were stored at 20 C until assayed; CF and AF were
stored at 70 C.
Determination of T4, T3, and rT3 in fetal fluids
Aliquots (400l) from each CF sample were taken to determine T4 and
rT3 concentrations individually. The rest was used to measure the T3
concentrations and the percent FT4, for which 1–4.5 ml are needed. With
AF, 200-l aliquots were sufficient to evaluate the percent FT4, but 3–6
ml were needed for the assays of T4 and T3. If necessary, CF or AF
samples were pooled according to equivalent gestational age. The io-
dothyronines were determined using highly sensitive and specific RIAs
after extensive extraction and purification with methods previously
described in detail (17, 18) with modifications to improve recovery.
Briefly, [131I]T4 and [
125I]T3 or [
131I]T4 and [
125I]rT3 were added to each
sample as internal tracers for recovery calculations. The samples were
extracted with a 2.5-fold volume of ethanol, and the ethanol extracts
were further purified on AG 1 2 resin columns (Bio-Rad Laboratories,
Inc., Richmond, CA), from which the iodothyronines were eluted with
70% acetic acid, pooled, evaporated to dryness, and extensively counted
for the calculation of individual recoveries. RIA buffer was then added,
and the iodothyronine contents were determined by RIAs in duplicate
at two dilutions. The limits of detection are 3.2 fmol T4, 1.0 pmol T3, and
1.5 pmol rT3/tube.
Verification of the presence of thyroid hormones in coelomic
fluid by HPLC
CF samples were extracted twice with ethanol-0.5 n HCl (10:0.5,
vol/vol). After centrifuging at 2000 rpm for 10 min, the supernatants
were mixed and neutralized with 200 l ammonia and passed through
Dowex AG 1 2 columns as described above. The iodothyronines were
eluted with 70% acetic acid and evaporated to dryness. The residue was
dissolved in 100 l 0.3 n ammonia and transferred to a Chromspher 5
FIG. 1. Schematic representation of the maternal-fetal unit during
the first (A) and second (B) trimesters of pregnancy. AC, Amniotic;
ECC, exocoelomic cavity; P, placenta; SYS, secondary yolk sac; U,
uterus; UC, umbilical chord; CL, chorion laeve (membranes in de-
velopment).
Calvo et al. • Normal Availability of FT4 to Early Fetal Tissues J Clin Endocrinol Metab, April 2002, 87(4):1768–1777 1769
 by on May 20, 2010 jcem.endojournals.orgDownloaded from 
C8 100  3-mm column (Chrompack, Middleburg, The Netherlands)
after addition of [131I]T4 and [
125I]T3. T4 and T3 were separated with an
isocratic gradient using 55% methanol and 45% 0.015 m ammonium
acetate, pH 3.5–4, at a rate of 0.6 ml/min. The fractions corresponding
to the labeled iodothyronines were evaporated to dryness, and 200 l
RIA buffer were added. The RIAs were performed as described above.
Percentages of free T4 and T3 in fetal fluids
The percent FT4 was determined in undiluted samples of CF and AF,
with slight modifications to the method described by Mendel et al. (19).
A 5-l aliquot of high specific activity [125I]T4 (350,000 cpm for CF and
70,000 cpm for AF) was added to 195 l sample and incubated at room
temperature for 1 h. A 180-l aliquot of each labeled CF or AF sample
was ultrafiltered using Microcon 10 microconcentrators (Amicon Divi-
sion, W.R. Grace Co., Beverly, MA) and centrifuged for 30 min at 3000
rpm. A measured volume of each ultrafiltrate and of the initial tracer was
added to 0.2 ml bovine serum and precipitated with 2.5 ml 10% tri-
chloroacetic acid; the pellet was counted after being washed twice with
the trichloroacetic acid solution. The radioactivity in the pellet was
calculated as a percentage of the tracer initially added. Each sample was
processed in duplicate. The percent FT4 and the total T4 determined by
RIA were used to calculate the concentrations of FT4.
The percent FT3 was determined in some undiluted CF samples using
the same procedure as that used to calculate the percent FT4, but only
approximately 100,000 cpm high specific activity [125I]T3 were added.
Drugs and reagents
T4, T3, and 3,5-diiodothyronine (3,5-T2) were obtained from Sigma (St.
Louis, MO). rT3 and 3,3-T2 were obtained from Henning Berlin GmbH
& Co. (Berlin, Germany), AG 1  2 resin was purchased from Bio-Rad
Laboratories, Inc. High specific activity [125I]T3, [
125I]T4, [
125I]rT3, and
[131I]T4 (3000 Ci/g) were synthesized by our laboratory as previ-
ously described (17).
Other assays
Hemoglobin content was measured in 10-l aliquots of CF and AF
(20). To assess the amounts of T4 and T3 from maternal blood that might
have contaminated CF or AF samples, we used the T4 and T3 concen-
trations in MS and assumed a value of 140 g/liter for hemoglobin and
a 50% hematocrit.
Total T4 in MS was measured by RIA, and free T4 in MS and FS was
measured by a two-step RIA method (Gammacoat kits provided by
Clinical Assays, INCSTAR, Stillwater, MN), T3 was determined using
the Amerlex RIA (Amersham Pharmacia Biotech, Little Chalfont, UK),
rT3 was determined using an RIA kit (Tickland, Liege, Belgium), FT3 in
MS was determined with the Dynotest FT3 kit from Brahms Diagnostica
GmbH (Berlin, Germany), TSH in MS and FS was determined by im-
munoradiometric assay, and T4-binding globulin (TBG) was determined
by RIA, with commercial kits (Behring, Marburg, Germany). The coef-
ficients of variation were less than 10 for T3, T4, and FT4; less than 5%
for TSH; and less than 10% for TBG and rT3.
Transthyretin (TTR) concentrations in MS and CF were determined
by immunonephelometry, using antihuman transthyretin Ab (Behring)
on the Behring nephelometer analyzer. The concentrations of albumin,
1-, 2-, -, and -globulins in CF were quantified by densitometry after
electrophoresis (14) with a 5% coefficient of variation.
Intact hCG was measured using a solid phase RIA based on the
principle of the sandwich assay (RIA-gnost hCG, Behring). The sensi-
tivity and intraassay coefficient of variations of this test were 1 IU/liter
and less than 5%, respectively.
To test likely interferences in the TSH RIA when samples contained
very high concentrations of hCG, we obtained purified hCG (provided
by Dr. A. F. Parlow from National Hormone and Pituitary Programs,
NIDDK, NIH). Native hCG obtained from pregnant human urine was
supplied by Sigma (St. Louis, MO).
Statistical analysis
The data were analyzed SPSS 6.1 (SPSS, Inc., Chicago, IL). All values
are expressed as the mean se. One-way ANOVA, followed by the least
significant difference post-hoc test, were used to compare mean values
of different series of data. Partial correlation analysis was performed,
and Pearson’s correlations coefficients were calculated; P  0.05 was
considered statistically significant. Most of the variables measured in the
present study were positively correlated with gestational age, and par-
tial correlation analyses disclosed that most of the correlations between
variables were spurious, as only a few persisted after correcting for
gestational age. Unless stated otherwise, only those correlations that
were independent of gestational age are considered here.
Results
Gestational age and maternal thyroid function
Table 1 summarizes the results obtained in the MS from
series A–C. Series C was further divided into groups C1 (first
trimester) and C2 (second trimester). First trimester levels of
T4 and TSH were the same in all groups, but T4 was higher
in second trimester samples. FT4 levels were lower in groups
B, C1, and C2 compared with A, whereas T3 levels were
higher. The T3/T4 molar ratio was increased in all groups
compared with group A. FT3 (not shown in Table 1) was only
measured in series C and increased between the first and
second trimester MS from 6.32  0.25 to 7.49  0.23 pmol/
liter (P 0.002), as did the FT3/FT4 molar ratio, from 0.305
0.017 to 0.427  0.016 (P  0.001).
Anti-TPO Ab titers above 200 U/ml were found in 6 of the
60 women where these were measured. Slightly elevated
TSH levels (6 mU/liter) were found in 4 of the 72 women,
with very high anti-TPO Ab titers present in 3 of these 4
women. Circulating T4, FT4, and T3 were within the normal
range for pregnancy in all 76 study women, except 1 with
normal TSH levels but T4 and FT4 values near the lower limits
for the normal population. All these features are consistent
with other reports for normal pregnant European and North
American women (21–23). No fetal samples were excluded
TABLE 1. Comparison of mean values (SE) of T4, T3, FT4, and TSH concentrations in the maternal plasma from series A, B, and C
n GA (wk) FT4 (pmol/liter) T4 (nmol/liter) T3 (nmol/liter) T3/T4 ratio ( 103) TSH (mU/liter)
A 13 7.9  0.6 24.0  3.0 145  12 1.77  0.14 12.7  1.1 2.0  0.8
B 20 9.6  0.2 15.4  0.6a 126  6 2.01  0.09(a) 16.3  0.8a 1.1  0.3
C1 15 9.6  0.3 21.4  1.1
b 133  7 2.28  0.10a 17.6  0.9a 1.1  0.4
C2 28 14.5  0.3
a,b,c 18.1  0.3a,b,c 156  5b,c 2.57  0.11a,b,c 16.7  0.8a,b 0.9  0.1
Range (9.0–25.0) (80–150) (1.20–3.10) (0.4–3.1)
Series C is divided into two groups, C1 and C2, according to a gestational age of 12 wk, or less or more than 12 wk, respectively. Numbers
in parentheses are the ranges of the values for nonpregnant adults given by the manufacturers of the kits.
a A significant difference vs. group A.
b A significant difference vs. group B.
c A significant difference between groups C1 and C2. When shown within parentheses, statistical significance was not reached, but 0.05 
P  0.10.
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on the basis of maternal thyroid status. The iodothyronine
levels and ratios suggest that women in groups B and C were
mildly iodine deficient (23, 24). The increase in plasma T3/T4
ratios with gestation also suggests that the iodine intake of
these women was not adequate for their increasing preg-
nancy requirements. Our results are therefore relevant to
pregnant women with mild to moderate iodine deficiency,
but without primary thyroid disease.
Verification by HPLC of the presence of thyroid hormones
in CF
The peaks of both iodothyronines, obtained by RIA, co-
incided with the peaks of in vitro added labeled T3 and T4
(Fig. 2), thus confirming the specificity of results obtained by
RIA in the purified CF.
Comparison of thyroid hormones concentration in
fetal fluids
Table 2 shows the comparison between T4, FT4, T3, and rT3
concentrations in CF and AF samples from all series (A–D).
No significant differences were found between the concen-
trations of T4 or T3 in first trimester CF from different series;
rT3 was higher in the C series and was 2- to 4-fold higher than
T4 in all series. The T3 levels are still tentative estimates, as
larger volumes of a greater number of CF samples are needed
for a more reliable assessment. Nevertheless, T3 levels ap-
peared to be 30–50 times lower than T4 and 100 times lower
than rT3. T4, T3, and rT3 were also found in those AF samples
in which the volume was sufficient to attempt their deter-
mination. The total concentrations of all three iodothyronines
were lower in AF than in age-paired first trimester CF sam-
ples, but FT4 levels were higher. Both T4 and rT3 concentra-
tions were higher in the second trimester AF samples. AF
volumes required for the determination of T3 were large,
excluding determinations in series C and D.
The contamination of CF and AF with maternal blood was
very slight, if any, and it barely affected the T4 values for the
fetal fluids. It accounted for 4% of the total CF T4 in one of
the very few hemoglobin-positive samples and even less in
the others.
rT3 levels correlated with T4 in both CF and AF (P 0.001).
No correlations were found in CF or AF between T3 and
either T4 or rT3, but the available T3 data were limited (see
above). Correlations of the different variables between the
two cavities were not found.
The percent FT4 and FT4 concentrations were measured in
CF and AF from series B–D. Initial results obtained with
samples from series B indicated that the CF and AF percent
FT4 values were much higher than those in MS. Despite the
more than 150-fold difference in total T4 between CF, or AF,
and MS, the concentrations of FT4 were of the same order of
magnitude and should, therefore, be potentially measurable
with FT4 kits used for human serum. We repeatedly at-
tempted this with several commercial kits [Dynotest FT4,
Brahms Diagnostica GmbH, Amerlex MAB FT4, Ortho-Clin-
ical Diagnostics (Amersham Pharmacia Biotech), Clinical As-
says Gammacoat two-step FT4, INCSTAR Corp. (Stillwater,
MN), and FT4 by equilibrium dialysis (Nichols Institute Di-
agnostics, San Juan Capistrano, CA)] and concluded they
cannot be used to measure FT4 in CF and AF, because the
standards in these kits mimic the protein content of human
sera, which is markedly different from that of CF and AF.
Results, including those obtained with the dialysis kit, were
not only unreliable when using CF or AF, but also when
using ultrafiltrates of MS.
We reverted to the ultrafiltration method described above
after having excluded likely sources of error. The possibility
was considered that the T4 contained in 350,000 cpm high
specific activity [125I]T4, added to 195l CF or AF, might have
raised the concentration of T4 in the sample beyond its bind-
ing capacity and result in an overestimation of the percent
FT4. This was investigated with eight different samples of CF
to which one half or one fourth the usual amount of [125I]T4
was added or to which the usual amount of tracer was added
plus increasing amounts of T4, ranging from 0.09–33 nmol/
liter. No significant correlation was found between the per-
cent FT4 values and the concentration of added T4 up to the
addition of 7 nmol T4/liter. At higher concentrations of
added T4, the percent FT4 started increasing in several sam-
ples, but in others it remained the same even after the ad-
dition of up to 33 nmol T4/liter. The capacity of the first
trimester AF samples to bind added T4 without altering the
measured percent FT4 was less than that of the CF, and for
this reason the [125I]T4 added to AF samples was reduced to
approximately 70,000 cpm. AF samples from the second tri-
mester were assayed as described for CF, because of the
sudden increase in protein content and T4 binding capacity
compared with those of the first trimester AF.
Figure 3 shows the total T4 concentration, the percent FT4,
and the FT4 concentration in matched samples of CF and AF.
The mean percent FT4 in CF was much higher than that in MS
(0.42% vs. 0.012–0.028%), and even higher (21.9%) in first
trimester AF. There was a sharp decrease in the percent FT4
(to 0.38%), between the end of the first and the beginning of
the second trimester, which corresponds to the period when
the fetus starts producing urine (10, 11, 14). In both extraem-
bryonic cavities the total T4 concentration changed inversely
to that of percent FT4. The resulting concentrations of FT4 in
the different compartments were buffered and much more
similar to each other than the very different concentrations
FIG. 2. Identity of the elution profiles of labeled T4 and T3 with the
iodothyronine concentrations determined by RIA. CF to which tracer
amounts of [125I]T3 and [
131I]T4 were added was separated by HPLC.
The three peaks of open circles correspond, left to right, to the radio-
labeled iodide, T3 and T4, respectively. The profiles obtained by RIA
are shown by black circles for T3 and by black diamonds for T4.
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of total T4. In both compartments FT4 correlated with T4 (r
0.86; P  0.001 for CF and r  0.55; P  0.014 for AF). The
FT4 concentrations of both compartments were also corre-
lated (r  0.84; P  0.005).
The values of FT3 obtained for CF are tentative. The mean
percent FT3 corresponding to 28 samples was 0.78  0.08%,
higher than the percent FT4 in the same fluid. The CF samples
used for this determination were not the same ones used for
the tentative determination of T3, and individual FT3 concen-
trations could not be calculated. Using the mean percent FT3
value and the mean tentative T3 concentration, a value of 0.19
pmol/liter was estimated for FT3. This would be no more than
3% of that in first trimester MS (6.32  0.25 pmol/liter).
TTR was present in CF, and its concentration increased
with gestational age (r 0.82; P 0.001), with values ranging
from 0.30 fmol/liter at 7 wk to about 0.56 fmol/liter between
9–11 wk. The concentrations of 1-, 2-, and -globulin in CF
increased significantly with gestational age, from 15 to 67
mg/dl for 1-globulin, from 8 to 45 mg/dl for 2-globulin,
and from 31 to 105 mg/dl for -globulin. Changes in the con-
centrations of all of these proteins were gestational age depen-
dent and independent of maternal thyroid status. Total T4 also
increased with gestational age, and a positive correlation was
found between CF T4 and TTR (r 0.62; P 0.01) and between
T4 and 1-, 2-, and -globulin concentrations. However, only
the correlation between T4 and 1-globulin persisted after ad-
justing for gestational age (r  0.74; P  0.01).
Contrary to the increase in hCG concentrations occurring
in MS during the first trimester, ranging in the present series
from 16,665–175,500 IU/liter between 5 and 10 wk gestation,
the hCG concentrations decreased in CF from 385,000 to
81,000 IU/liter. No correlation persisted between T4 and hCG
after correction for gestational age in either CF or MS.
Thyroid hormones in fetal serum
Individual data for T4, FT4, T3, TBG, and TSH in FS are
shown as a function of advancing gestation in Fig. 4. T4 and
T3 were undetectable using commercial kits in all but a few
FIG. 3. T4 and FT4 levels and percent FT4 in CF and AF obtained up
to and including 12 wk gestation () or later, up to 17 wk (o). Values
are the mean  SE. T4 and FT4 are expressed in the same units to
permit direct comparisons between both variables. An asterisk dis-
closes statistically significant differences between the first trimester
and early second trimester AF samples. CF can no longer be obtained
after 12 wk gestation, and only first trimester data are shown.
TABLE 2. Comparison of T4, T3, and rT3 concentrations in coelomic and amniotic fluids
Series Gestational age (wk) T4 (nmol/liter)
Coelomic fluid
rT3 (nmol/liter)
FT4 (pmol/liter) T3 (nmol/liter)
A 8.3  2.0 (6) 0.96  0.19 (12) n.d 0.030  0.013 (9) 2.86  0.97 (6)
B 9.6  1.0a (7) 0.95  0.11 (17) n.d 0.020  0.003 (5) 2.10  0.50 (11)
C1 9.8  0.3 (16)
a 1.28  0.13 (8) 2.50  0.26 (6) n.d. 5.48  0.66 (8)a,b,d
C2 14.5  0.3 (27)
a,b,c1,d — — — —
D 9.5  0.2 (9)a,c2 0.90  0.13 (20) 2.82  0.37 (19) n.d. 2.56  0.36 (20)c1
Amniotic fluid
FT4 (pmol/liter) T3 (nmol/liter)
A 10.1  0.6 (6) 0.087  0.007 (2) n.d. 0.012  0.007 (7) 0.39  0.09 (6)
B 9.7  0.4 (7) 0.063  0.009 (6) 17.22  1.81 (6) 0.006  0.001 (6) n.d.
C1 9.8  0.3 (16) 0.173  0.073 (7) 11.86  5.56 (7) n.d. 1.49  0.63 (7)
a,d
C2 14.6  0.3 (27)
a,b,c1 2.041  0.594 (6)a,b,c1,d 6.45  1.93 (4) n.d. 3.43  1.00 (3)a,c1,d
D 9.6  0.4 (9)c2 0.086  0.020 (8) 20.43  6.75 (7) n.d. 0.21  0.07 (8)c1,c2
Values are means SE, with number of values given in parentheses. n.d., Not determined; —, there were no CF samples available more than
12 wk GA.
a A significant difference vs. group A.
b A significant difference vs. group B.
c1, c2Significant differences vs. groups C1 or C2.
d A significant difference vs. group D.
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of the samples from older fetuses. Both, however, could be
measured, after extraction and purification of larger volumes
of serum, using the method described for CF and AF. Mean
values (se) were 6.88  0.72 nmol/liter for total T4 and
0.78  0.18 nmol/liter for total T3 at a mean gestational age
of 14.5  0.3 wk. There was insufficient FS to measure the
percent FT4 by the same ultrafiltration method as that used
for CF and AF, but there was sufficient FS for the determi-
nation of FT4 using a commercial kit tested for human sera,
including samples with very low TBG concentrations. The
mean FT4 concentration was 5.69  0.40 pmol/liter, a value
not significantly different from that found for second tri-
mester AF samples (Fig. 3). TBG in FS was undetectable
(0.091 fmol/liter) up to 15 wk, after which the mean value
for six samples was 0.12  0.01 fmol/liter. FT4 in FS corre-
lated with the T4 concentration in the same fluid (r  0.90;
P  0.001) and T3 with T4 (r  0.89; P  0.001) and FT4 (r 
0.68; P  0.017).
TSH in FS ranged from 2.9–7.2 mU/liter, with a mean
value of 4.31  0.26 mU/liter (Fig. 4), and did not correlate
with T4, T3, or FT4. We had not anticipated these concentra-
tions of TSH in the serum of the human fetus before the
primary capillary plexus between the hypothalamus and the
median eminence develops at 18–20 wk. TSH in FS was
higher than that in MS; no correlation was found between
TSH in FS and MS. We tested the possibility that despite the
high specificity of the TSH Ab described by the manufac-
turers of the TSH kits, the very high hCG concentrations in
the FS and MS might cross-react with it, and this might result
in an overestimation of the true TSH concentration. This
possibility was excluded; we added up to 400,000 IU/liter of
both hCG and native hCG to several samples of human
serum without any effect on the resulting TSH value.
Comparisons between extraembryonic fluids and
fetal serum
As the T4 and T3 concentrations in CF and AF are referred
to the volume of these fluids, we compared them with those
of the corresponding volume of the fluid in the fetal circu-
lation, namely, blood, not serum. The concentrations in blood
have been calculated from those in serum by assuming a 50%
hematocrit. The concentrations of T4 or T3 in CF, AF, and fetal
blood were plotted simultaneously against gestational age.
These plots showed that, with development, there was a
progressive and continuous increase in total T4 and T3 in the
embryonic and fetal fluids bathing the yolk sac and fetal
tissues. The data fitted exponential functions of age, with r
0.89 for total T4 and r 0.87 for total T3 (P 0.001 for both).
On the contrary, as shown in Fig. 5, FT4 concentrations in the
embryonic and fetal fluids remained fairly constant.
Concentrations of iodothyronines in FS could only be com-
pared with those in second trimester AF, because age-
matched CF cannot be obtained: no correlations were found
between both fluids for T4, FT4, or T3, but this might be due
to the very small number of second trimester AF samples for
which all of these data were available.
Comparison of hormones in fetal fluids with maternal
thyroid status
Most of the gestational age-related changes in parameters
of maternal thyroid hormone status of the present study
agree with those already described by others for early preg-
nancy (23). Thus, TBG increased from 5 to 17 wk (r  0.65;
P  0.001). Circulating T4 (Table 1) also increased with ad-
vancing gestation (r 0.34; P 0.011) and was higher in the
second trimester compared with the first (P  0.001).
Changes in total T3 were similar, with second trimester val-
ues higher than those in the first trimester (P 0.001). There
was no appreciable difference in TSH between the trimesters.
FT4 was higher in the first trimester compared with the
second (Table 1) and negatively correlated to gestational age
(r  0.40; P  0.013). In the present study, however, FT3
concentrations and FT3/FT4 ratios increased from the first to
the second trimester. In the first trimester, T4 in CF was
positively correlated to T4 in MS (r  0.61; P  0.001) and in
the second trimester T4 in FS was correlated to FT4 in MS (r
0.57; P  0.14), but T3 in FS was not correlated to MS T3 or
FT3. Neither T4 nor FT4 in AF correlated with these variables
in MS in either the first or second trimester.
Figure 5 shows individual values of T4 and FT4 for series
C, which comprised not only samples of CF and AF, but also
those of fetal and maternal blood. These concentrations were
derived from the serum values, assuming a 50% hematocrit.
The highest T4 concentrations in fetal blood were at least
FIG. 4. Changes with gestational age in the concentrations of T4, FT4, T3, TBG, and TSH in the FS. Individual values obtained for series C
are shown. The shaded areas show the limits of detection when commercial kits are used for the determinations. Data corresponding to FT4,
TBG, and TSH were obtained with such kits. The concentrations of T4 and T3 were below the limits of detection in all samples obtained at less
than 17 wk gestation. The individual data for T4 and T3 shown were obtained after extraction, purification, and RIA, as performed for CF and
AF samples, using larger volumes of serum than permitted by the kits. i.h., In-house method; c.k., commercial kit.
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10-fold lower than those in maternal blood and 100-fold
lower, or more, in CF and AF compared with maternal blood.
In contrast, the differences between FT4 in the fetal and
maternal compartments were much smaller than those ob-
served for total T4. The mean FT4 concentration in CF (see Fig.
3) reached 45% of the mean maternal blood value (9.4 pmol
FT4/liter blood, derived from 18.4 pmol FT4/liter serum),
and 53% of the reference blood value for the general popu-
lation (7.64 pmol FT4/liter blood, derived from 15.3 pmol/
liter serum). The mean FT4 in AF was similar to that in
maternal blood, and the mean FT4 in fetal blood reached 43%
of the maternal value (51% of that in the general euthyroid
adult population).
Discussion
Total T4 concentrations increase steadily during the first
half of pregnancy in both maternal and fetal compartments.
T3 concentrations in fetal fluids are at least 10-fold lower than
those of T4, whereas rT3 in CF and AF is higher than that in
the maternal circulation. T4 in fetal fluids is directly related
to the thyroxinemia of euthyroid mothers, whereas no cor-
relations were found for T3 or rT3 between the maternal and
fetal compartments. Findings are consistent with present
concepts of maternal-fetal transfer of molecules (13). During
the first trimester maternal T4 is transferred into the exocoe-
lomic cavity and subsequently into the fetal gut and circu-
lation via the secondary yolk sac; during the second trimes-
ter, it is transferred directly into fetal blood.
Synthesis of TTR by the yolk sac epithelium (14, 15, 25)
then facilitates transfer of FT4 from the CF into the yolk sac,
and its early synthesis by choroid plexus epithelium (26)
enhances the transfer of T4 into cerebral structures. The com-
position of the AF is more likely to reflect fetal metabolism
of the iodothyronines, although limited exchanges between
the two fluid cavities occur during the first trimester (13). The
marked change in AF T4 between the first and second tri-
mesters is probably linked to the onset of glomerular filtra-
tion and direct excretion of fetal proteins into this cavity (10).
The present results neither confirm nor exclude maternal
T3 transfer into first trimester CF. T3 in the second trimester
FS is not correlated to T3 or FT3 in MS, but to the T4 and FT4
concentrations in the same fetal compartment, suggesting
that the T3 and FT3 in early fetal fluids are not transferred
from the mother, but result from metabolism of the maternal
T4 that reached fetal tissues.
The low concentrations in fetal fluids of T3, the high con-
centrations of rT3, and the high molar rT3/T4 ratios suggest
that iodothyronines transferred from maternal to fetal fluids
in early pregnancy undergo the same inactivating processes
that are characteristic of later fetal development (27–36).
These are attributed to high activities of inner ring 5-iodo-
thyronine deiodinase (D-III), an inner ring deiodinating
isoenzyme with preference for T3 over T4 as substrate, and
of sulfo-transferases, producing T4 and T3 sulfates. High
D-III activities have been described in the decidua, most
placental cellular types and membranes, and many fetal tis-
sues. Also present in placenta and some fetal tissues (i.e.
brain, brown adipose tissue, and pituitary) is the 5D-II iso-
form, which permits local intracellular generation of T3 from
T4. 5D-I, an important source of the systemic T3 needed for
the supply of intracellular T3 to other tissues (i.e. liver, lung, and
kidney), appears much later during perinatal development.
D-III activity in uterus and placenta constitutes an impor-
tant barrier for the transfer of maternal T4 and T3 to the fetal
compartment. D-III in placental membranes and fetal tissues
further inactivates the iodothyronines escaping the barrier
and is responsible, together with high sulfo-transferase ac-
tivities, for the low T3 and high rT3 levels characteristic of
FIG. 5. A and B compare the concen-
trations of T4 (left panel) and FT4 (right
panel) in CF, AF, and fetal blood with
those in maternal blood. The shaded ar-
eas correspond to the 95% confidence
interval for the adult euthyroid popu-
lation. The ordinate scale is logarithmic
for both T4 and FT4 concentrations.
This comparison stresses the greater
similarity of CF, AF, and fetal FT4 con-
centrations with those in the maternal
compartment compared with the more
than 100-fold differences between the
fetal and maternal concentrations of T4.
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fetal compartments. Studies in animal models and humans
show that placental 5D-III activity is not affected by maternal
thyroid hormone status (29, 37); a decrease in the amount of
substrate, namely maternal circulating T4 and T3, results in
lower concentrations of the hormones in fetal fluids. This
conclusion is strongly supported by the positive correlations
between T4 in fetal fluids and circulating T4 or FT4 levels in
their euthyroid mothers.
The T4 in fetal fluids that is actually available to tissues,
namely FT4, is much higher than expected in adults with
comparably low circulating T4. FT4 in fetal fluids reaches
concentrations similar to those exerting biological effects in
adults. Such concentrations may well be biologically relevant
for the early developing brain, as T3-occupied nuclear re-
ceptors are already found (2, 3, 34). Our results reconcile
apparently contradictory observations, namely, that mater-
nal thyroid hormones are needed by the early developing
brain, but at the same time they are prevented from reaching
the fetal compartment during a period of development when
the mother is their only source. Present findings show that,
if such a barrier were not effective and T4 and T3 in fetal and
maternal fluids were the same, the FT4 and FT3 available to
developing tissues could be excessive and potentially
harmful.
The unexpected similarity of the concentrations of FT4 in
maternal and fetal fluids is related to major qualitative and
quantitative differences in thyroid hormone-binding pro-
teins. TBG in first trimester fetal fluid is not detectable, and
its concentration in early FS is very low. TTR (38) and some
of the T4-binding proteins of the 1-globulin fraction, such as
1-antitrypsin, 1-antichymotrypsin, and 1-fetoprotein (39–
41), are present in CF at low concentrations. Thus, the pro-
portion of maternal T4 that reaches the fetal fluid cavities and
is found in the free form, i.e. the percent FT4, is much higher
than that in adults; the resulting FT4 concentrations in fetal
and maternal fluids become similar. The protein composition
of fetal fluids is defined ontogenically and is not affected by
maternal thyroid status. As the thyroid hormone-binding
capacity in each fluid is far in excess of the total concentra-
tions of iodothyronines, the FT4 in the fetal fluid compart-
ments is determined by their total T4. The latter, in turn, is
correlated to circulating maternal T4 (first trimester) or FT4
(second trimester); a decrease in maternal T4 or FT4 thus
results in a concordant decrease in FT4 in fetal fluids and,
consequently, in tissues.
T4 and T3 have been found in different tissues between 9
and 18 wk gestation (2, 3, 34), providing direct evidence that
FT4 (and possibly FT3) reaching fetal fluids actually enters
tissues; the concentration of T3 in the cortex at 13 wk ges-
tation may actually reach 50–60% of the values reported for
adults (42), with 20–34% thyroid hormone nuclear receptor
occupancy by T3 (43). These estimates are approximate and
do not take into account that different tissues and organs or
cell types within the same organ have specific temporal pat-
terns of development, and their requirements for T3 may
vary widely. This would be of special importance early in life,
when either a deficient or an excessive supply of hormone
would result in the premature or delayed onset of biological
events and an irreversible loss of opportunity for orderly
development.
The ontogenetically programmed expression of 5D-II and
5D-III is an important mechanism to achieve tightly con-
trolled concentrations of T3 in cerebral structures at different
stages of development. It is frequently observed during de-
velopment even in tissues other than the brain and in mam-
malian and nonmammalian species (34, 44, 45), overcoming
the fact that these are all exposed to the same concentrations
of FT4 or FT3 in fetal fluids. The importance of the availability
of T4 over T3 becomes evident, as T4 is the initial substrate of
these regulatory cascades that are determined ontogenically
at cell-specific developmental stages. Relatively high T3 lev-
els and nuclear receptor occupancy by T3 have indeed been
found in the early human cortex (2, 3, 43) despite very low
FT3 in fetal fluids, but present results show that FT4 is rel-
atively normal and could provide enough substrate for gen-
eration of sufficient T3 by 5D-II deiodination. This enzyme
is already present in the cortex at 11–14 wk gestational age
(46). Intracellular T3 concentrations in other fetal tissues, such
as liver, heart, and lung, however, were still undetectable at
18 wk gestation (2, 3, 43). These tissues depend mostly on
systemic T3 generated by the 5D-I, an enzyme that is only
expressed much later, near term or postnatally.
In the rat, maternal T4 is the principal source of intracel-
lular T3 in the early developing brain (47, 48). Moreover, its
local generation from T4 of maternal origin protects the fetal
brain from T3 deficiency in cases of fetal thyroid failure,
because cerebral 5D-II activity increases markedly in re-
sponse to a minor decrease in T4 (49, 50), compensating for
the decreased availability of substrate by generating more T3.
These findings in rat fetuses correspond to a period of brain
development that occurs during the second half of human
pregnancy. Whether they are operative in earlier stages of
pregnancy has not been fully established. Karmarkar et al.
(46) found that 5D-II activity in the human cerebral cortex
at 11–14 wk gestation did not respond to a decrease in ma-
ternal T4. This suggests that down-regulation of 5D-II ac-
tivity by T4 is delayed with respect to the timing of onset of
its expression. A response was detected later, at 15–18 wk,
but appeared to be inadequate, because T3 in the cortex
remained low. Therefore, in the absence of a compensatory
regulatory response of cerebral 5D-II early in development,
a decrease in maternal T4 would ultimately result in a lower
intracellular T3 concentration.
Biological effects of thyroid hormone have not yet been
identified in early human fetal brain, but recent studies show
that maternal hypothyroidism early in pregnancy results in
the inappropriate expression of specific genes in the fetal rat
brain (51, 52) and in irreversible alterations of the migration
of cells in the cortex and hippocampus (53). The latter are also
observed in the progeny from iodine-deficient rat dams (54)
that are hypothyroxinemic but not hypothyroid. A very short
period of goitrogen-induced mild hypothyroxinemia early in
pregnancy is also sufficient to induce both abnormal migra-
tion and permanent neurological damage (i.e. increased au-
diogenic seizure susceptibility) (55). Alterations of migration
are easily visualized by a significant increase in heterotopic
cells in the subcortical white matter. This increase has been
observed in human fetuses from an iodine-deficient area (56),
suggesting that human cerebral cytoarchitecture and the es-
tablishment of normal circuits are also affected by early ma-
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ternal hypothyroxinemia; in humans the two main waves of
migration of cells in the neocortex occur before midgestation,
with peaks at 8–10 and 12 wk gestation (57).
In all FS samples we examined in this study TSH values
were relatively high and did not correlate with maternal
TSH, confirming a previous report with fewer samples (16).
Studies on sera from normal and anencephalic human fe-
tuses have shown that TSH bioactivity is greatly increased
with respect to that circulating in the mothers (58, 59), con-
firming that it is not of maternal origin. Some of the results
suggest the existence of sources of fetal TSH that are not
under hypothalamic neuroendocrine control. In the rat the
brain is one of these sources (60). A TSH receptor has been
found in early human fetal brain and human astrocytes in
primary culture (61). This receptor mediates extrathyroidal
cAMP-independent biological effects of TSH, among which
is, interestingly, the stimulation of 5D-II in astroglial cells
(62).
In summary, we here show that first trimester fetal tissues
are exposed to concentrations of FT4 in the same range as
those available to adult tissues. These concentrations depend
ultimately on the circulating maternal levels of T4 or FT4.
Even in euthyroid women, a decrease in this maternal supply
results in lower concentrations of FT4 in fetal fluids and,
consequently, of T4 available to the developing brain. We
here propose that this T4 would determine the amount of T3,
generated locally by 5D-II deiodination, that ultimately
binds to thyroid hormone nuclear receptors in different brain
structures and triggers biological responses early in gestation
in orderly sequence. Ensuring maternal T4 levels appropriate
for the stage of pregnancy, regardless of whether TSH is
increased or whether overt or subclinical hypothyroidism is
detected, may decrease the risk of neurodevelopmental de-
fects in the child (5). A major cause of maternal hypothy-
roxinemia worldwide is an inadequate iodine intake, which
is easily avoided by encouraging pregnant women to take
iodine supplements from early pregnancy even in countries
such as the U.S. (1).
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